Zobrazeno 1 - 10
of 484
pro vyhledávání: '"bezlotoxumab"'
Autor:
K. E. Popruga, V. V. Makarov
Publikováno v:
Журнал инфектологии, Vol 15, Iss 4, Pp 35-41 (2024)
Clostridioides difficile is a leading cause of diarrhea and pseudomembranous colitis associated with antibiotic therapy. Hypervirulent strains of C. difficile, such as ribotype 027, have high mortality rates. Recurrent C. difficile infection is extre
Externí odkaz:
https://doaj.org/article/f6349871981844288134bf922b47dc31
Autor:
Marianna Meschiari, Alessandro Cozzi-Lepri, Adriana Cervo, Guido Granata, Carlotta Rogati, Erica Franceschini, Stefania Casolari, Paola Tatarelli, Daniele Roberto Giacobbe, Matteo Bassetti, Simone Mornese Pinna, Francesco Giuseppe De Rosa, Francesco Barchiesi, Benedetta Canovari, Carolina Lorusso, Giuseppe Russo, Giovanni Cenderello, Antonio Cascio, Nicola Petrosillo, Cristina Mussini
Publikováno v:
International Journal of Infectious Diseases, Vol 131, Iss , Pp 147-154 (2023)
Objectives: Bezlotoxumab (BEZ) is a promising tool for preventing the recurrence of Clostridioides difficile infection (rCDI). The aim of the study was to emulate, in a real-world setting, the MODIFY trials in a cohort of participants with multiple r
Externí odkaz:
https://doaj.org/article/9d585e06570540408104ba9291e0d967
Autor:
Sergey M. Zakharenko
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 50, Iss 6, Pp 377-391 (2023)
Clostridium difficile was reclassified in 2016 under a new name of Clostridioides difficile. In 2021 to 2022, some changes were implemented into the main clinical guidelines on the diagnosis and treatment of infections caused by this pathogen. A two-
Externí odkaz:
https://doaj.org/article/2d2c05a29a914e0d8dcd12e6efb298e0
Autor:
Lamiaa Abd El-Fattah MADKOUR
Publikováno v:
Mediterranean Journal of Infection, Microbes and Antimicrobials, Vol 12, Iss 1 (2023)
Clostridioides difficile is the predominant worldwide etiology of healthcare-associated diarrhea. Furthermore, C. difficile infections (CDIs) have been designated by the Centers for Disease Control and Prevention as an urgent threat, which is the hig
Externí odkaz:
https://doaj.org/article/8fc12c476b584a5f828e83e9538791f4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Florian Jakobs, Sebastian Marcel Wingen-Heimann, Julia Jeck, Anna Kron, Oliver Andreas Cornely, Florian Kron
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1
Externí odkaz:
https://doaj.org/article/14fc3fe852fd4c44a7d653c8c745b65c
Autor:
Alice Annalisa Medaglia, Alessandro Mancuso, Chiara Albano, Giuseppe Zinna, Luca Pipitò, Cinzia Calà, Rita Immordino, Raffaella Rubino, Silvia Bonura, Baldassare Canino, Giuseppe Calamusa, Claudia Colomba, Pier Luigi Almasio, Antonio Cascio
Publikováno v:
Antibiotics, Vol 12, Iss 5, p 837 (2023)
Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking. The purpose of this study
Externí odkaz:
https://doaj.org/article/2371b6d27f4d4ea6842a9c1b062ed67d
Autor:
Daniele Roberto Giacobbe, Silvia Dettori, Stefano Di Bella, Antonio Vena, Guido Granata, Roberto Luzzati, Nicola Petrosillo, Matteo Bassetti
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 3, Pp 481-494 (2020)
Abstract Clostridioides difficile infection (CDI) and recurrent CDI (rCDI) remain associated with a reduction in the patients’ quality of life and with increased healthcare costs. Bezlotoxumab is a monoclonal antibody against toxin B of C. difficil
Externí odkaz:
https://doaj.org/article/5c438fe8141e47019044cc4c96aa3191
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.